건선 치료 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of psoriasis treatment Market

The global psoriasis treatment market size was valued at USD 29.15 billion in 2025 and is projected to grow to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034. Market growth is supported by rising disease prevalence, increasing adoption of biologic therapies, expanding awareness programs, and strong clinical development pipelines. In 2025, North America dominated the market with a share of 74.83%, driven by high biologic usage, extensive insurance coverage, and robust regulatory approvals.

Psoriasis is a chronic autoimmune inflammatory disorder characterized by rapid skin cell proliferation, plaque formation, inflammation, and joint involvement in psoriatic arthritis. Approximately 30%-40% of psoriasis patients develop psoriatic arthritis, increasing long-term therapy needs. Plaque psoriasis remains the most common form, accounting for 80%-90% of total cases, creating sustained demand for long-term pharmacologic management.

Market Drivers

The growing prevalence of psoriasis remains a primary driver. An estimated 2%-3% of the global population suffers from psoriasis, increasing demand for effective systemic and topical therapies. Governments and healthcare organizations are promoting early diagnosis and disease awareness, improving treatment initiation rates.

Another major driver is the strong pipeline of biologic drugs targeting inflammatory cytokines. Regulatory approvals for IL-17, IL-23, and TYK2 inhibitors are improving clinical outcomes and increasing physician confidence in biologic prescribing. Expanded indications for pediatric and psoriatic arthritis populations further increase patient eligibility.

Market Trends

A dominant trend is the shift toward biologic therapies that target specific immune pathways with improved safety and efficacy. Biologics offer higher clearance rates, longer remission periods, and reduced systemic toxicity compared to conventional therapies. Manufacturers are investing heavily in next-generation biologics and biosimilars to improve affordability and expand market access.

Teledermatology adoption is also improving patient monitoring and prescription continuity, particularly in rural regions and during public health emergencies, supporting long-term medication adherence.

Market Restraints

High treatment costs remain a significant barrier, especially in developing countries. Biologic therapies involve high manufacturing expenses, leading to elevated out-of-pocket costs for patients. Limited reimbursement frameworks restrict biologic adoption in low-income populations, delaying therapy initiation and reducing market penetration.

Topical and systemic alternatives remain cost-effective but often lack the long-term disease control achieved by biologics, creating access disparities across regions.

Segmentation Analysis

By Drug Class

The market is segmented into TNF inhibitors, interleukin inhibitors, and others. TNF inhibitors dominated with 41.31% market share in 2026, driven by long-established clinical usage and biosimilar availability. However, interleukin inhibitors are registering the fastest growth due to superior efficacy, improved safety profiles, and expanding clinical trial programs.

By Type

By type, the market includes plaque psoriasis, psoriatic arthritis, and others. Plaque psoriasis accounted for 41.31% market share in 2026, driven by high disease prevalence and large patient populations. Psoriatic arthritis is experiencing rapid growth due to improved diagnostic rates and expanded biologic indications.

By Product Type

Based on product type, the market is segmented into biologics and non-biologics. Biologics dominated with 90.73% share in 2026, reflecting strong adoption of targeted therapies such as IL-17 and IL-23 inhibitors. Non-biologics continue to grow due to oral drug approvals and lower cost accessibility.

By Route of Administration

The market is categorized into oral, parenteral/systemic, and topical. Parenteral/systemic therapies accounted for 83.48% share in 2026, supported by widespread biologic administration through injections and infusions. Oral therapies are expanding due to convenience and increasing TYK2 inhibitor approvals.

By Distribution Channel

Distribution includes hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominated in 2024 due to wide accessibility and refill convenience, while online pharmacies are expanding rapidly through home delivery services and biosimilar partnerships.

Regional Outlook

North America generated USD 21.81 billion in 2025, supported by advanced biologic adoption and strong reimbursement systems. The U.S. market reached USD 21.75 billion in 2026, driven by FDA approvals and Medicare pricing negotiations.

Europe holds strong demand, with Germany valued at USD 1.05 billion and the U.K. at USD 0.63 billion in 2026, supported by regulatory approvals and national healthcare coverage. Asia Pacific is the fastest-growing region, with China at USD 0.74 billion, Japan at USD 0.61 billion, and India at USD 0.27 billion in 2026, driven by clinical trial expansion and government awareness programs. Latin America and Middle East & Africa are growing through expanding healthcare access and disease awareness.

Competitive Landscape

Key players include AbbVie, Johnson & Johnson, Novartis, Pfizer, Eli Lilly, Amgen, LEO Pharma, UCB, and Sun Pharmaceutical Industries. Market leaders focus on biologic innovation, biosimilar expansion, and multi-indication labeling strategies. Strategic acquisitions and global clinical programs strengthen product pipelines and market coverage.

Report Coverage

The report analyzes market size and value for 2025, 2026, and 2034, with segmentation by drug class, type, product type, route of administration, and distribution channel. It includes regional and country-level market values, regulatory trends, product launches, clinical pipeline developments, and competitive strategies shaping the global psoriasis treatment industry.

Conclusion

The psoriasis treatment market is expanding from USD 29.15 billion in 2025 to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034, driven by rising disease burden, biologic therapy innovation, and expanding global treatment access. Dominance of biologics, strong performance of parenteral therapies, and leadership by North America reflect advanced treatment adoption, while rapid growth in Asia Pacific highlights increasing healthcare investment and regulatory support. Continued innovation in immune-targeted therapies, biosimilars, and oral treatment options is strengthening long-term market sustainability across diverse patient populations.

Segmentation By Drug Class

• TNF Inhibitors
• Interleukins Inhibitors
• Others

By Type

• Plaque Psoriasis
• Psoriatic Arthritis
• Others

By Product Type

• Biologics
• Non-Biologics

By Route of Administration

• Oral
• Parenteral/Systemic
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country)
  • U.S. (By Type)
  • Canada (By Type)
• Europe (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.K. (By Type)
  • Germany (By Type)
  • France (By Type)
  • Italy (By Type)
  • Spain (By Type)
  • Scandinavia (By Type)
  • Rest of Europe (By Type)
• Asia Pacific (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Japan (By Type)
  • China (By Type)
  • India (By Type)
  • Australia & New Zealand (By Type)
  • Rest of Asia Pacific (By Type)
• Latin America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil (By Type)
  • Mexico (By Type)
  • Rest of Latin America (By Type)
• Middle East & Africa (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC (By Type)
  • South Africa (By Type)
  • Rest of the Middle East & Africa (By Type)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Psoriasis, By Key Countries, 2025
• 4.2. Overview: Regulatory Scenario & Reimbursement Scenario, By Key Countries/Region
• 4.3. New Product Launches, By Key Players
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Key Industry Developments, By Key Players
• 4.6. Impact of COVID-19 on the Market

5. Global Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. TNF Inhibitors
  • 5.1.2. Interleukins Inhibitors
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Plaque Psoriasis
  • 5.2.2. Psoriatic Arthritis
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Product Type
  • 5.3.1. Biologics
  • 5.3.2. Non-Biologics
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Oral
  • 5.4.2. Parenteral/Systemic
  • 5.4.3. Topical
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. TNF Inhibitors
  • 6.1.2. Interleukins Inhibitors
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Plaque Psoriasis
  • 6.2.2. Psoriatic Arthritis
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Product Type
  • 6.3.1. Biologics
  • 6.3.2. Non-Biologics
• 6.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.4.1. Oral
  • 6.4.2. Parenteral/Systemic
  • 6.4.3. Topical
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Type
  • 6.6.2. Canada
    • 6.6.2.1. By Type

7. Europe Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. TNF Inhibitors
  • 7.1.2. Interleukins Inhibitors
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Plaque Psoriasis
  • 7.2.2. Psoriatic Arthritis
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Product Type
  • 7.3.1. Biologics
  • 7.3.2. Non-Biologics
• 7.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.4.1. Oral
  • 7.4.2. Parenteral/Systemic
  • 7.4.3. Topical
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K
    • 7.6.1.1. By Type
  • 7.6.2. Germany
    • 7.6.2.1. By Type
  • 7.6.3. France
    • 7.6.3.1. By Type
  • 7.6.4. Spain
    • 7.6.4.1. By Type
  • 7.6.5. Italy
    • 7.6.5.1. By Type
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Type
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Type

8. Asia Pacific Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. TNF Inhibitors
  • 8.1.2. Interleukins Inhibitors
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Plaque Psoriasis
  • 8.2.2. Psoriatic Arthritis
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Product Type
  • 8.3.1. Biologics
  • 8.3.2. Non-Biologics
• 8.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.4.1. Oral
  • 8.4.2. Parenteral/Systemic
  • 8.4.3. Topical
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Type
  • 8.6.2. China
    • 8.6.2.1. By Type
  • 8.6.3. India
    • 8.6.3.1. By Type
  • 8.6.4. Australia & New Zealand
    • 8.6.4.1. By Type
  • 8.6.5. Rest of Asia Pacific
    • 8.6.5.1. By Type

9. Latin America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. TNF Inhibitors
  • 9.1.2. Interleukins Inhibitors
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Plaque Psoriasis
  • 9.2.2. Psoriatic Arthritis
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Product Type
  • 9.3.1. Biologics
  • 9.3.2. Non-Biologics
• 9.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.4.1. Oral
  • 9.4.2. Parenteral/Systemic
  • 9.4.3. Topical
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Type
  • 9.6.2. Mexico
    • 9.6.2.1. By Type
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Type

10. Middle East & Africa Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. TNF Inhibitors
  • 10.1.2. Interleukins Inhibitors
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Plaque Psoriasis
  • 10.2.2. Psoriatic Arthritis
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Product Type
  • 10.3.1. Biologics
  • 10.3.2. Non-Biologics
• 10.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.4.1. Oral
  • 10.4.2. Parenteral/Systemic
  • 10.4.3. Topical
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
    • 10.6.1.1. By Type
  • 10.6.2. South Africa
    • 10.6.2.1. By Type
  • 10.6.3. Rest of Middle East & Africa
    • 10.6.3.1. By Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Novartis AG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Pfizer Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. LEO Pharma A/S
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Merck & Co., Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Amgen Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Eli Lilly and Company
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Evelo Biosciences, Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. UCB S.A.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Sun Pharmaceutical Industries Ltd.
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)